innovation compounding semaglutide Innovative Primary Care Helps Patients Navigate Access to GLP Weight Loss Medications Concerns Surrounding Compounded GLP-1s Mount

Endocr Rev 25 : 426457 Diano S et al

They found that, as first-line agents, SGLT2is and GLP-1RAs would improve T2DM outcomes, but their costs would need to fall by at least 70% to be cost-effective [84]

That's not a reason for alarm, but it is a reason coverage decisions and clinical guidelines will keep evolving as the data matures Forbes What's fascinating isn't just the rise in GLP-1 use it's how quickly they're reshaping conversations around obesity

They make the physician feel like the conversation was worth having

34 The AMPLITUDE-O trial demonstrated significant dose-dependent effects of efpeglenatide on HF hospitalisation in patients with T2D and CVD or renal disease, along with one risk factor

Endocrinologists and cardiologists in major cities are gaining experience with GLP-1 medications through diabetes management applications, facilitating confidence in prescribing for obesity indications